Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Besremi (Ropeginterferon Alfa-2b-njft) is a pegylated interferon alfa-2b biologic medication manufactured by PharmaEssentia Corporation. It is FDA-approved for the treatment of polycythemia vera (PV) in adults — a rare blood cancer where the bone marrow produces too many red blood cells, increasing the risk of blood clots, stroke, and heart attack.
Besremi is the only interferon specifically FDA-approved for polycythemia vera. It is self-administered as a subcutaneous injection every two weeks using a prefilled syringe. Unlike daily oral medications like Hydroxyurea, Besremi's every-2-week dosing schedule offers convenience, and it has been shown to reduce the JAK2 mutant clone burden over time — a unique disease-modifying benefit.
Besremi works by binding to the interferon alfa/beta receptor (IFNAR) on cell surfaces, which activates the JAK-STAT signaling pathway. This triggers antiproliferative, immunomodulatory, and antiviral responses in the body. In polycythemia vera specifically, Besremi preferentially targets and reduces the JAK2 V617F mutant clone — the abnormal cells responsible for overproducing red blood cells. By reducing this mutant clone burden over time, Besremi helps normalize blood cell counts and lowers the risk of dangerous thrombotic events like blood clots and strokes.
Besremi comes in a single concentration. The starting dose is typically 100 mcg (or 50 mcg if transitioning from Hydroxyurea), titrated up in 50 mcg increments every 2 weeks based on blood count response, to a maximum of 500 mcg every 2 weeks.
Besremi scores a 35 out of 100 on our findability scale, meaning it can be quite difficult to obtain. As a specialty biologic dispensed exclusively through specialty pharmacies, Besremi is not available at retail pharmacies like CVS or Walgreens. Patients must work with their hematologist to arrange delivery through a specialty pharmacy, which ships the medication directly to their home. While Besremi itself is not formally listed on the FDA drug shortage list, the broader interferon class has experienced significant supply disruptions — the related drug Pegasys (Peginterferon Alfa-2a) has been in shortage since 2024, driving increased demand for Besremi and occasionally causing delays in fulfillment.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Besremi is prescribed by specialists who manage blood disorders and blood cancers:
Because polycythemia vera is a rare condition requiring specialized monitoring (regular blood counts, liver function tests, psychiatric evaluations), Besremi is not typically prescribed by primary care physicians. Patients are usually referred to a hematologist for diagnosis and ongoing treatment management.
No, Besremi is not a controlled substance. It is not scheduled by the DEA and does not carry any risk of abuse or dependence. However, it is a specialty biologic medication that requires a prescription, specialty pharmacy dispensing, and regular medical monitoring due to its serious potential side effects, including a Boxed Warning for psychiatric risks.
Important: Besremi carries a Boxed Warning for risk of serious mental health problems including depression, suicidal ideation, and suicide. It can also worsen autoimmune disorders, ischemic disorders, and infectious disorders. Patients should report any mood changes, new symptoms, or worsening conditions to their doctor immediately.
No known food or drink interactions. Always inform your healthcare provider of all medications you are taking before starting Besremi.
Besremi represents an important treatment option for adults with polycythemia vera — it is the only interferon therapy specifically FDA-approved for this condition. Its every-2-week dosing and ability to reduce the disease-driving JAK2 mutant clone make it a compelling choice, especially for patients who cannot tolerate or have not responded well to Hydroxyurea.
However, Besremi comes with significant considerations: the high cash price ($9,700–$11,000 per injection), the need for specialty pharmacy dispensing, and serious potential side effects including its Boxed Warning for psychiatric risks. The good news is that PharmaEssentia's SOURCE program can reduce costs to $0 for eligible commercially insured patients, and a patient assistance program exists for uninsured individuals.
If you're struggling to access Besremi or need help navigating specialty pharmacy logistics, Medfinder can help you find this medication and connect you with resources to make treatment more accessible.
%2C%20Color%3DOriginal.png)
